LivaNova (NASDAQ:LIVN) Shares Down 4.4% - Time to Sell?

Key Points

• LivaNova's stock declined by 4.4% to $50.05, with trading volume significantly down by 88% compared to its average volume.
• Analysts have varying opinions on LivaNova, with **buy** ratings from Needham & Company and an upgrade to **strong-buy** by Wall Street Zen, while the consensus target price stands at $59.71.
• LivaNova reported quarterly earnings that exceeded expectations, with **$1.05 earnings per share** and revenue of **$352.50 million**, marking a 10.6% increase compared to the previous year.

Shares of LivaNova PLC (NASDAQ:LIVN - Get Free Report) fell 4.4% during mid-day trading on Wednesday . The stock traded as low as $49.69 and last traded at $50.05. 79,765 shares changed hands during trading, a decline of 88% from the average session volume of 688,258 shares. The stock had previously closed at $52.38.

Wall Street Analyst Weigh In

A number of analysts have recently commented on LIVN shares. Needham & Company LLC reissued a "buy" rating and issued a $64.00 price objective on shares of LivaNova in a research note on Wednesday, September 3rd. The Goldman Sachs Group set a $55.00 price objective on shares of LivaNova and gave the company a "neutral" rating in a research report on Wednesday. Barclays increased their target price on shares of LivaNova from $55.00 to $58.00 and gave the company an "equal weight" rating in a research note on Thursday, August 21st. Finally, Wall Street Zen upgraded shares of LivaNova from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 9th. Five analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $59.71.

LivaNova Stock Performance

The firm has a market cap of $2.76 billion, a price-to-earnings ratio of -13.01 and a beta of 0.96. The firm's 50 day moving average is $52.18 and its 200-day moving average is $45.24. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.09 and a current ratio of 1.29.

LivaNova (NASDAQ:LIVN - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $1.05 earnings per share for the quarter, topping analysts' consensus estimates of $0.84 by $0.21. The company had revenue of $352.50 million during the quarter, compared to analysts' expectations of $332.20 million. LivaNova had a positive return on equity of 14.57% and a negative net margin of 16.13%.The business's quarterly revenue was up 10.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.93 earnings per share. Sell-side analysts anticipate that LivaNova PLC will post 2.85 earnings per share for the current fiscal year.

Institutional Investors Weigh In On LivaNova

A number of institutional investors have recently added to or reduced their stakes in LIVN. GAMMA Investing LLC lifted its position in shares of LivaNova by 182.5% in the 2nd quarter. GAMMA Investing LLC now owns 630 shares of the company's stock worth $28,000 after acquiring an additional 407 shares during the period. State of Wyoming acquired a new position in shares of LivaNova in the second quarter valued at $31,000. EverSource Wealth Advisors LLC lifted its position in LivaNova by 998.4% in the second quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company's stock worth $32,000 after purchasing an additional 639 shares during the period. UMB Bank n.a. boosted its stake in LivaNova by 340.5% during the first quarter. UMB Bank n.a. now owns 837 shares of the company's stock worth $33,000 after buying an additional 647 shares in the last quarter. Finally, CWM LLC increased its holdings in LivaNova by 52.3% in the 1st quarter. CWM LLC now owns 871 shares of the company's stock valued at $34,000 after buying an additional 299 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.